

# Vassilis Georgoulas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8243055/publications.pdf>

Version: 2024-02-01

86  
papers

3,908  
citations

136885

32  
h-index

123376

61  
g-index

87  
all docs

87  
docs citations

87  
times ranked

4831  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2011, 13, R59.	2.2	327
2	Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 3756-3762.	0.8	268
3	Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2177-2184.	0.8	246
4	Different Prognostic Value of Cytokeratin-19 mRNA-Positive Circulating Tumor Cells According to Estrogen Receptor and HER2 Status in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5194-5202.	0.8	238
5	Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 2593-2600.	3.2	220
6	Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2008, 10, R80.	2.2	128
7	<i>ESR1</i> Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 1500-1510.	3.2	125
8	Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2008, 3, e3695.	1.1	121
9	Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in 2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients. <i>PLoS ONE</i> , 2011, 6, e15980.	1.1	114
10	Hypoxia-inducible factor-1 $\alpha$ and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2009, 11, R84.	2.2	111
11	A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients. <i>Journal of Immunology Research</i> , 2014, 2014, 1-12.	0.9	106
12	Paclitaxel and docetaxel in the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2603-2616.	0.9	105
13	Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. <i>BMC Cancer</i> , 2014, 14, 651.	1.1	97
14	Apoptotic Circulating Tumor Cells in Early and Metastatic Breast Cancer Patients. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1886-1895.	1.9	96
15	Phosphorylation of FAK, PI-3K, and Impaired Actin Organization in CK-positive Micrometastatic Breast Cancer Cells. <i>Molecular Medicine</i> , 2007, 13, 79-88.	1.9	80
16	Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. <i>Breast Cancer Research</i> , 2011, 13, R60.	2.2	74
17	Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401775012.	1.4	61
18	High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. <i>Lung Cancer</i> , 2004, 44, 363-368.	0.9	60

#	ARTICLE	IF	CITATIONS
19	Breast Cancer Metastasis Suppressor-1 Promoter Methylation in Primary Breast Tumors and Corresponding Circulating Tumor Cells. <i>Molecular Cancer Research</i> , 2013, 11, 1248-1257.	1.5	54
20	Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. <i>Breast Cancer Research</i> , 2014, 16, 485.	2.2	51
21	Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis. <i>Supportive Care in Cancer</i> , 2012, 20, 1823-1829.	1.0	50
22	Evaluation of Isolation Methods for Circulating Tumor Cells (CTCs). <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 411-419.	1.1	50
23	Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0123683.	1.1	49
24	BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients's Outcome. <i>PLoS ONE</i> , 2013, 8, e84604.	1.1	48
25	Docetaxel in the treatment of advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1207-1222.	1.1	47
26	Caveolin-1 regulates EGFR signalling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. <i>Cancer Biology and Therapy</i> , 2009, 8, 1470-1477.	1.5	46
27	A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group. <i>Journal of Chemotherapy</i> , 2013, 25, 49-55.	0.7	45
28	Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 525-534.	1.1	44
29	Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial. <i>Lung Cancer</i> , 2008, 59, 57-63.	0.9	41
30	A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 594-606.	1.1	38
31	PIK3CA Hotspot Mutation Scanning by a Novel and Highly Sensitive High-Resolution Small Amplicon Melting Analysis Method. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 697-704.	1.2	37
32	FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). <i>Breast Cancer Research and Treatment</i> , 2010, 119, 95-104.	1.1	36
33	Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients. <i>Scientific Reports</i> , 2021, 11, 2313.	1.6	32
34	Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPII- $\alpha$ , TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide. <i>PLoS ONE</i> , 2013, 8, e74611.	1.1	31
35	Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. <i>Breast Cancer Research</i> , 2006, 8, R36.	2.2	30
36	Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. <i>PLoS ONE</i> , 2017, 12, e0181211.	1.1	30

#	ARTICLE	IF	CITATIONS
37	Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. <i>Oncotarget</i> , 2017, 8, 5309-5322.	0.8	30
38	A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 35-42.	1.1	29
39	Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). <i>European Journal of Cancer</i> , 2015, 51, 1511-1528.	1.3	27
40	Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment. <i>Lung Cancer</i> , 2018, 124, 270-278.	0.9	27
41	Oxaliplatin as First-Line Treatment in Inoperable Biliary Tract Carcinoma. <i>Oncology</i> , 2006, 70, 280-284.	0.9	25
42	Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 361-368.	1.1	25
43	TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC). <i>Scientific Reports</i> , 2017, 7, 45351.	1.6	25
44	Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2015, 17, 113.	2.2	24
45	Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 851-863.	0.9	21
46	The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization. <i>Breast Cancer Research</i> , 2019, 21, 86.	2.2	21
47	A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1239-1245.	1.1	20
48	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2363-2389.	0.9	19
49	Prognostic Significance of the Detection of Peripheral Blood CEACAM5mRNA-Positive Cells by Real-Time Polymerase Chain Reaction in Operable Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 165-173.	3.2	19
50	Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 767-775.	1.1	19
51	Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment. <i>Lung Cancer</i> , 2019, 135, 33-39.	0.9	19
52	Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR. <i>Cancers</i> , 2021, 13, 2736.	1.7	19
53	Docetaxel (Taxotere) in the Treatment of Non-Small Cell Lung Cancer. <i>Current Medicinal Chemistry</i> , 2002, 9, 869-877.	1.2	18
54	Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types. <i>Lancet Oncology</i> , 2017, 18, 556-557.	5.1	18

#	ARTICLE	IF	CITATIONS
55	Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib. <i>Scientific Reports</i> , 2018, 8, 2238.	1.6	13
56	Î multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 63-68.	1.1	12
57	MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer. <i>Targeted Oncology</i> , 2019, 14, 285-293.	1.7	11
58	Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2021, 22, 925.	1.8	11
59	Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma. <i>Journal of Neuro-Oncology</i> , 2010, 97, 291-294.	1.4	10
60	Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1505-1519.	0.9	10
61	CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989575.	1.4	10
62	Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 875-884.	1.1	9
63	DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment. <i>Cancers</i> , 2021, 13, 5974.	1.7	9
64	Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 351-356.	1.1	8
65	Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy. <i>Cancers</i> , 2022, 14, 1574.	1.7	8
66	Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1037-1048.	1.5	7
67	Detyrosinated Î±-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 154.	1.1	7
68	PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patientsâ€™ CTCs. <i>Cancers</i> , 2022, 14, 1731.	1.7	7
69	Plasmablastic lymphoma of the breast in an immunocompetent patient: long-lasting complete response induced by chemotherapy and autologous stem cell transplantation. <i>Anticancer Research</i> , 2014, 34, 5111-5.	0.5	6
70	Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(âˆ™) breast cancer receiving salvage treatment with everolimus/exemestane. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 277-287.	1.1	5
71	Association of epithelial-to-mesenchymal transition circulating tumor cells in non-small cell lung cancer (NSCLC) molecular subgroups. <i>Journal of Thoracic Disease</i> , 2017, 9, 4817-4820.	0.6	4
72	Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study. <i>Minerva Ginecologica</i> , 2019, 71, 182-190.	0.8	4

#	ARTICLE	IF	CITATIONS
73	A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer. <i>Anticancer Research</i> , 2010, 30, 4335-42.	0.5	4
74	A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 449-456.	1.1	2
75	The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2015, 7, 439-449.	1.7	2
76	Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3237.	1.7	2
77	A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 785-791.	1.1	1
78	A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 415-422.	1.1	1
79	Detection of circulating tumor cells in the peripheral blood of patients with small cell lung cancer (SCLC) using both the CellSearch platform and immunofluorescence: Correlation with clinicopathological features.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7573-7573.	0.8	1
80	Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20086-e20086.	0.8	1
81	A dose escalation study of leucovorin (LV) and 48-hour continuous infusion of 5-fluorouracil in combination with cyclophosphamide and vinorelbine in pretreated patients with metastatic breast cancer. <i>Anticancer Research</i> , 2004, 24, 4217-21.	0.5	1
82	A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 121-128.	1.1	0
83	The optimum duration of front-line chemotherapy. <i>Lancet Oncology</i> , The, 2014, 15, 1187-1188.	5.1	0
84	Effect of exemestane plus everolimus on CTC counts and Ki-67 expression on CTCs in patients with advanced hormone receptor-positive, HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11042-11042.	0.8	0
85	Effect of 2 <sup>nd</sup> line pazopanib (PZN) on the number and phenotype of CTCs in patients with small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8562-8562.	0.8	0
86	PD-L1+CD4+ T cells and soluble PD-L1 as prognostic factors to anti-PD-1 immunotherapy in advanced non small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24091-e24091.	0.8	0